Antineoplastic Drug-Associated Interstitial Lung Disease
Conditions
Interventions
The group without drug damage:None
Non-tumor interstitial lung disease:None
Drug-Associated Interstitial Lung Disease:None
Healthy control group:None
Sponsors
Fuzhou University Affiliated Provincial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Adults >=18 years of age with the ability to independently provide written informed consent, fulfilling the criteria for either the oncology or control cohort, capable of undergoing baseline BALF and peripheral blood sampling at treatment commencement or time of diagnosis, and consenting to serial blood sampling at 2-4 weeks and 8-12 weeks following treatment initiation.
Exclusion criteria
Exclusion criteria: 1.Active infection or established non-drug-related etiology of ILD (including but not limited to connective tissue disease-associated ILD, environmental or occupational exposure-induced ILD, active radiation pneumonitis); 2.prolonged pre-enrollment treatment with moderate-to-high dose systemic corticosteroids or immunosuppressive agents that would compromise baseline evaluation; 3.absolute contraindications to bronchoscopic procedures or inability to comply with scheduled key follow-up assessments; 4.severe decompensated comorbid conditions; 5.pregnancy or lactation period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Predictive Performance of Drug-Associated ILD Diagnostic Model; | — |
Secondary
| Measure | Time frame |
|---|---|
| Dynamic Changes of Peripheral Blood Biomarkers; | — |
Countries
China
Contacts
Public ContactBaosong Xie
Fuzhou University Affiliated Provincial Hospital
Outcome results
None listed